Table 5:
Biologic | Clinical Response Rate | Clinical Remission Rate |
---|---|---|
Infliximab | 69% | 39% |
Adalimumab | 50% | 17% |
Golimumab | 55% | 18% |
Vedolizumab | 47% | 17% |
Biologic | Clinical Response Rate | Clinical Remission Rate |
---|---|---|
Infliximab | 69% | 39% |
Adalimumab | 50% | 17% |
Golimumab | 55% | 18% |
Vedolizumab | 47% | 17% |